Priya Singhal
Corporate Officer/Principal chez BIOGEN INC.
Fortune : 1 M $ au 31/03/2024
Profil
Priya Singhal is currently the Chief Medical Officer at Biogen, Inc. She previously worked as the Head-Medical Affairs & Vice President at Vertex Pharmaceuticals, Inc. from 2008 to 2012.
She also held a position as the Head-Research & Development at Zafgen, Inc. Dr. Singhal holds a doctorate degree from the University of Mumbai and a graduate degree from Harvard T.H.
Chan School of Public Health.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
BIOGEN INC.
0,00% | 02/04/2024 | 4 886 ( 0,00% ) | 1 M $ | 31/03/2024 |
Postes actifs de Priya Singhal
| Sociétés | Poste | Début |
|---|---|---|
| BIOGEN INC. | Corporate Officer/Principal | 02/10/2023 |
Anciens postes connus de Priya Singhal
| Sociétés | Poste | Fin |
|---|---|---|
| VERTEX PHARMACEUTICALS INCORPORATED | Chief Tech/Sci/R&D Officer | 01/01/2012 |
| LARIMAR THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | - |
Formation de Priya Singhal
| University of Mumbai | Doctorate Degree |
| Harvard T.H. Chan School of Public Health | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| VERTEX PHARMACEUTICALS INCORPORATED | Health Technology |
| BIOGEN INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Zafgen, Inc.
 Zafgen, Inc. BiotechnologyHealth Technology Zafgen, Inc. is a biopharmaceutical company, which engages in the development of novel therapies for patients affected by complex metabolic diseases. It focuses on the study of MetAP2 inhibitors in both common and rare metabolic disorders. The firm also advancing programs for type 2 diabetes, Prader-Willi syndrome, and liver diseases. The company was founded on November 22, 2005 and is headquartered in Boston, MA. | Health Technology |
